| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 31.01.
| Cellectis Plant Sciences Announces the Signature of a Strategic Partnership with SESVanderHave in Sugar Beet | | 66 | Business Wire |
| Regulatory News:
Cellectis (Paris:ALCLS) plant sciences, the plant genome engineering
company and subsidiary of Cellectis (Alternext: ALCLS), announces today...
Mehr lesen zu:
Cellectis Plant Sciences Announces the Signature of a Strategic Partnership with SESVanderHave in Sugar Beet | |
| 30.01.
| Changes in the Group's Scientific Division and Appointment of the CEO of Cellectis Plant Sciences | | 47 | Business Wire |
| Regulatory News:
Cellectis (Paris:ALCLS)(Alternext: ALCLS), the French genome
engineering specialist, is announcing the operational withdrawal of
...
Mehr lesen zu:
Changes in the Group's Scientific Division and Appointment of the CEO of Cellectis Plant Sciences | |
| 23.01.
| Precision BioSciences Announces that the US Patent Office Rejects All Claims to Cellectis Patent | | 39 | Business Wire |
| Precision BioSciences, Inc., a leader in the field of genome
engineering, today announced that the United States Patent and Trademark
Office (PTO) has issued a first,...
Mehr lesen zu:
Precision BioSciences Announces that the US Patent Office Rejects All Claims to Cellectis Patent | |
| 17.01.
| Medicago, Cellectis to enhance therapeutic proteins | | - | Pharma Bus Review |
| 16.01.
| Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology | | 21 | PR Newswire |
| QUEBEC CITY, QC and SAINT PAUL, MN, Jan. 16, 2012 /PRNewswire/ - Medicago Inc.
(MDG: TSX), a biotechnology company focused on developing highly
effective and competitive vaccines based on proprietary...
Mehr lesen zu:
Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology | |
| 16.01.
| Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology | | 36 | Business Wire |
| Regulatory News:
Medicago Inc. (TSX: MDG), a biotechnology company focused on
developing highly effective and competitive vaccines based on
proprietary...
Mehr lesen zu:
Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology | |
| 09.01.
| Cellectis Launches a Partnership with Total for Exploratory Research into Microalgae-Based Substitutes for Oil Products | | 43 | Business Wire |
| Regulatory News:
Cellectis (Paris:ALCLS), the French genome engineering specialist, is
today announcing that it has signed an agreement with Total to develop...
Mehr lesen zu:
Cellectis Launches a Partnership with Total for Exploratory Research into Microalgae-Based Substitutes for Oil Products | |
| 03.01.
| Cellectis plant sciences and Bayer CropScience strengthen genome engineering partnership | | 69 | Business Wire |
| Regulatory News:
Cellectis plant sciences, the plant genome engineering company and
subsidiary of Cellectis (Paris:ALCLS), today announced that it has
...
Mehr lesen zu:
Cellectis plant sciences and Bayer CropScience strengthen genome engineering partnership | |
| 08.12.
| Cellectis bioresearch and Syngene Announce Partnership on the Development of Customized Cell Lines | | 68 | Business Wire |
| Regulatory News:
Cellectis bioresearch, the specialist in genome customization and
commercial subsidiary of Cellectis (Paris:ALCLS), and Syngene
International...
Mehr lesen zu:
Cellectis bioresearch and Syngene Announce Partnership on the Development of Customized Cell Lines | |
| 05.12.
| Cellectis Signs a License Agreement Under Patents Covering Uses of Homologous Recombination With Global Pharmaceutical Company | | 25 | Business Wire |
| Regulatory News:
Cellectis (Paris:ALCLS), the genome engineering specialist (Alternext:
ALCLS), is announcing that it has signed a license agreement with
...
Mehr lesen zu:
Cellectis Signs a License Agreement Under Patents Covering Uses of Homologous Recombination With Global Pharmaceutical Company | |
| 07.11.
| Cellectis Announces the Final Completion of the Acquisition of Cellartis and €50 Million Financing Round Reserved for the FSI and Mr. Pierre Bastid | | 36 | Business Wire |
| Regulatory News:
Not for release, publication or distribution, directly or indirectly, in
Australia, Canada, Japan or the United States
Friday...
Mehr lesen zu:
Cellectis Announces the Final Completion of the Acquisition of Cellartis and €50 Million Financing Round Reserved for the FSI and Mr. Pierre Bastid | |
| 02.11.
| Cellectis shareholders approve the acquisition of Cellartis. | | 54 | Business Wire |
| Cellectis decides to raise €50 million from the FSI and Mr. Pierre
Bastid, and to grant free share purchase warrants to all existing
shareholders.
...
Mehr lesen zu:
Cellectis shareholders approve the acquisition of Cellartis. | |
| 24.10.
| Appointment of Philippe Valachs as Cellectis' General Secretary | | 50 | Business Wire |
| Regulatory News:
Cellectis (Paris:ALCLS) Cellectis, the genome engineering specialist, is
announcing the appointment of Philippe Valachs as Company Secretary.
...
Mehr lesen zu:
Appointment of Philippe Valachs as Cellectis' General Secretary | |
| 06.10.
| Cellectis: 2011 half-year earnings | | 49 | Business Wire |
| Resources strengthened to support growth across all the Group's
business lines, with limited cash burn
Important strategic moves implemented
...
Mehr lesen zu:
Cellectis: 2011 half-year earnings | |
| 06.10.
| Precision BioSciences Sues Cellectis for Patent Infringement | | 52 | Business Wire |
| Precision BioSciences, Inc., the world leader in rational genome
engineering, today announced that it has filed a lawsuit against
Cellectis SA and its affiliates Cellectis...
Mehr lesen zu:
Precision BioSciences Sues Cellectis for Patent Infringement | |
| 03.10.
| Cellectis Issues Statement Regarding Patent Suits on Meganuclease Technology | | 45 | Business Wire |
| Regulatory News:
Cellectis SA (Paris:ALCLS), the French genome engineering company,
provided an update today regarding its recent patent litigations against...
Mehr lesen zu:
Cellectis Issues Statement Regarding Patent Suits on Meganuclease Technology | |
| 26.09.
| The ETICS Project, Led by CYTOO in Collaboration With Cellectis bioresearch and the CEA, to Receive Euro 7.6 Million in Funding From OSEO | | 23 | PR Newswire |
| PARIS, Sept. 26, 2011 /PRNewswire/ -- CYTOO, a company that specializes in cell-based assays (Grenoble, France), has joined up with Cellectis bioresearch, the specialist in genome customization and...
Mehr lesen zu:
The ETICS Project, Led by CYTOO in Collaboration With Cellectis bioresearch and the CEA, to Receive Euro 7.6 Million in Funding From OSEO | |
| 07.09.
| Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011 | | 22 | PR Newswire |
| PARIS, Sept. 7, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced that its nuclease production capacity has increased ten-fold in 2011, significantly...
Mehr lesen zu:
Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011 | |
| 06.09.
| Cellectis to Present at Two Upcoming International Investor Conferences | | 29 | PR Newswire |
| PARIS, Sept. 6, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, will present at the UBS Global Life Sciences Conference in New York City on September 20...
Mehr lesen zu:
Cellectis to Present at Two Upcoming International Investor Conferences | |
| 24.08.
| Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock | | 25 | Business Wire |
| Regulatory News:
This agreement opens a new field of applications for Cellectis
bioresearch technologies
Cellectis bioresearch, the genome...
Mehr lesen zu:
Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock | |
